Bausch + Lomb, an esteemed global eye health company, has broadened its portfolio by purchasing Johnson & Johnson Vision’s Blink product line for $106.5 million.

The acquisition, financed using existing cash, underscores Bausch + Lomb’s ongoing commitment to enhancing consumer convenience in over-the-counter (OTC) eye care.

The Blink range, now under Bausch + Lomb’s umbrella, encompasses a variety of eye and contact lens rewetting drops designed to provide immediate and long-lasting symptom relief.

The acquired product lineup includes Blink Tears Lubricating Eye Drops, Blink Tears Preservative Free Lubricating Eye Drops, Blink GelTears Lubricating Eye Drops, Blink Triple Care Lubricating Eye Drops, Blink Contacts Lubricating Eye Drops, and Blink-N-Clean Lens Drops.

John Ferris — Bausch + Lomb Consumer executive vice president said: “There’s a growing need for relieving the symptoms of dry eyes and dry contact lenses, and OTC products are often the first option consumers choose.

“The addition of Blink expands our robust portfolio of OTC eye care brands, enabling us to provide more choices for consumers and eye care professionals.”

The acquisition follows Bausch + Lomb’s recent definitive agreement with Novartis to purchase the non-steroid eye drop XIIDRA (lifitegrast ophthalmic solution) 5%, widely utilized for the treatment of dry eye disease (DED) symptoms. This acquisition strategy aligns with Bausch + Lomb’s mission to enhance people’s vision and improve their quality of life.

  Bausch + Lomb, John Ferris, Johnson & Johnson